repaglinide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antihyperglycaemics 2366 135062-02-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • repaglinide
  • (S)-(+)-Repaglinide
  • prandin
  • enyglid
  • surepost
  • Molecular weight: 452.60
  • Formula: C27H36N2O4
  • CLOGP: 5.66
  • LIPINSKI: 1
  • HAC: 6
  • HDO: 2
  • TPSA: 78.87
  • ALOGS: -5.19
  • ROTB: 10
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
4 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 1.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 1.47 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 56 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.35 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 7.80 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.02 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.87 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 22, 1997 FDA NOVO NORDISK INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypoglycaemia 636.02 17.30 262 8173 53319 50543370
Lactic acidosis 328.05 17.30 143 8292 33212 50563477
Acute kidney injury 316.61 17.30 278 8157 227780 50368909
Hypoglycaemic coma 159.84 17.30 43 8392 2290 50594399
Hyperkalaemia 117.02 17.30 82 8353 48007 50548682
Drug interaction 109.97 17.30 150 8285 199471 50397218
Pemphigoid 70.13 17.30 29 8406 5878 50590811
Diabetes mellitus inadequate control 69.85 17.30 37 8398 13108 50583581
Sopor 65.54 17.30 41 8394 19838 50576851
Blood glucose increased 64.42 17.30 69 8366 71255 50525434
Transcription medication error 53.00 17.30 11 8424 186 50596503
Metabolic acidosis 50.78 17.30 46 8389 38779 50557910
Prothrombin consumption time prolonged 47.79 17.30 8 8427 37 50596652
Anuria 46.94 17.30 27 8408 11217 50585472
Product prescribing error 46.91 17.30 34 8401 20927 50575762
Hyperglycaemia 45.40 17.30 42 8393 36363 50560326
Hepatocellular injury 40.48 17.30 34 8401 25913 50570776
Confusional state 39.32 17.30 92 8343 185836 50410853
Rhabdomyolysis 39.22 17.30 40 8395 38987 50557702
Pancreatitis acute 38.81 17.30 32 8403 23780 50572909
Drug ineffective 33.82 17.30 53 8382 819280 49777409
Rash maculo-papular 33.72 17.30 31 8404 26610 50570079
Dehydration 31.73 17.30 75 8360 152374 50444315
Medication error 30.94 17.30 34 8401 36070 50560619
Pain 29.42 17.30 32 8403 578871 50017818
Poverty of speech 27.17 17.30 7 8428 314 50596375
Resting tremor 25.66 17.30 8 8427 718 50595971
Diabetic ketoacidosis 24.99 17.30 22 8413 17850 50578839
Renal failure 23.86 17.30 54 8381 106579 50490110
Anaemia 23.79 17.30 94 8341 252362 50344327
Somnambulism 23.74 17.30 13 8422 4911 50591778
Cholestasis 23.65 17.30 25 8410 25376 50571313
Subacute cutaneous lupus erythematosus 23.37 17.30 10 8425 2205 50594484
Autoimmune haemolytic anaemia 23.36 17.30 12 8423 3987 50592702
Hypoglycaemic encephalopathy 23.23 17.30 6 8429 272 50596417
Dermatitis bullous 21.65 17.30 14 8421 7159 50589530
Vascular purpura 21.62 17.30 8 8427 1206 50595483
Rheumatoid arthritis 21.28 17.30 4 8431 202546 50394143
Euglycaemic diabetic ketoacidosis 21.05 17.30 10 8425 2809 50593880
Asthenia 20.46 17.30 106 8329 318936 50277753
Hepatitis fulminant 20.25 17.30 10 8425 3058 50593631
Disorientation 19.94 17.30 27 8408 35457 50561232
Fall 19.26 17.30 108 8327 334824 50261865
Arthralgia 18.37 17.30 28 8407 438674 50158015
Drug reaction with eosinophilia and systemic symptoms 18.10 17.30 23 8412 28401 50568288
Hypokalaemia 17.97 17.30 43 8392 87949 50508740
Peripheral swelling 17.91 17.30 6 8429 205930 50390759
Renal impairment 17.68 17.30 39 8396 75622 50521067
Gingival abscess 17.64 17.30 6 8429 708 50595981
Pancreatitis 17.54 17.30 28 8407 42586 50554103

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypoglycaemia 596.31 15.68 304 10002 48042 29516179
Lactic acidosis 267.84 15.68 153 10153 30094 29534127
Hypoglycaemic coma 164.82 15.68 51 10255 2112 29562109
Acute kidney injury 163.59 15.68 313 9993 264954 29299267
Drug interaction 90.78 15.68 207 10099 197178 29367043
Pemphigoid 55.56 15.68 34 10272 7547 29556674
Diabetes mellitus inadequate control 54.17 15.68 40 10266 12094 29552127
Oesophageal perforation 54.14 15.68 17 10289 738 29563483
Cardiac failure 45.30 15.68 91 10215 79196 29485025
Erythromelalgia 40.59 15.68 8 10298 45 29564176
Coronavirus infection 38.36 15.68 20 10286 3268 29560953
Cholestasis 38.29 15.68 44 10262 23418 29540803
Bradyphrenia 36.35 15.68 21 10285 4193 29560028
Sopor 35.75 15.68 30 10276 10904 29553317
Hyperkalaemia 35.68 15.68 71 10235 61321 29502900
Polymerase chain reaction 35.29 15.68 8 10298 95 29564126
Acute coronary syndrome 32.64 15.68 30 10276 12295 29551926
Hepatocellular injury 31.61 15.68 38 10268 21205 29543016
Anuria 30.82 15.68 26 10280 9515 29554706
Eosinophilia 30.32 15.68 38 10268 22123 29542098
Hyperkinetic heart syndrome 29.00 15.68 7 10299 111 29564110
Renal failure 28.97 15.68 99 10207 118500 29445721
Hyperglycaemia 28.02 15.68 46 10260 34241 29529980
Pericardial haemorrhage 26.33 15.68 15 10291 2916 29561305
Urine leukocyte esterase positive 24.44 15.68 8 10298 397 29563824
Toxic skin eruption 24.39 15.68 23 10283 9734 29554487
Anaemia 21.89 15.68 132 10174 200819 29363402
Haemoglobinuria 21.51 15.68 8 10298 581 29563640
Hyperthermia 21.25 15.68 21 10285 9409 29554812
Supraventricular extrasystoles 21.06 15.68 13 10293 2928 29561293
Lung disorder 19.94 15.68 37 10269 30325 29533896
Drug ineffective 19.81 15.68 63 10243 363107 29201114
Glycosuria 19.32 15.68 9 10297 1153 29563068
Extrasystoles 19.08 15.68 13 10293 3461 29560760
Arteriovenous fistula site haematoma 19.07 15.68 4 10302 32 29564189
Thrombocytopenia 18.99 15.68 95 10211 134728 29429493
Haematoma 18.76 15.68 31 10275 23181 29541040
Cardio-respiratory arrest 18.76 15.68 49 10257 50552 29513669
Renal tubular necrosis 18.71 15.68 24 10282 14291 29549930
Hypoglycaemic encephalopathy 18.65 15.68 6 10300 282 29563939
Blood glucose decreased 18.62 15.68 22 10284 12047 29552174
Medication error 18.06 15.68 29 10277 21182 29543039
Metabolic acidosis 17.74 15.68 40 10266 37622 29526599
Vascular purpura 17.71 15.68 9 10297 1394 29562827
Prurigo 17.61 15.68 7 10299 609 29563612
Loss of consciousness 17.34 15.68 61 10245 73995 29490226
Blood lactic acid increased 17.17 15.68 15 10291 5751 29558470
Urine ketone body present 17.06 15.68 8 10298 1040 29563181
Gamma-glutamyltransferase increased 16.83 15.68 32 10274 26705 29537516
Hypomagnesaemia 16.42 15.68 25 10281 17443 29546778
Pancreatitis acute 16.36 15.68 30 10276 24355 29539866
Pancreatic carcinoma 16.26 15.68 16 10290 7134 29557087
Agranulocytosis 16.22 15.68 27 10279 20313 29543908
Blood glucose increased 15.95 15.68 51 10255 58933 29505288

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypoglycaemia 1113.32 13.83 524 17030 89368 64391810
Lactic acidosis 567.92 13.83 294 17260 61116 64420062
Acute kidney injury 432.42 13.83 568 16986 448672 64032506
Hypoglycaemic coma 333.51 13.83 97 17457 4177 64477001
Drug interaction 192.68 13.83 349 17205 361734 64119444
Hyperkalaemia 127.22 13.83 147 17407 100982 64380196
Pemphigoid 125.01 13.83 64 17490 12922 64468256
Diabetes mellitus inadequate control 97.95 13.83 65 17489 21256 64459922
Sopor 87.23 13.83 69 17485 29592 64451586
Anuria 71.04 13.83 51 17503 18913 64462265
Hepatocellular injury 67.58 13.83 72 17482 45163 64436015
Metabolic acidosis 64.91 13.83 88 17466 70870 64410308
Hyperglycaemia 60.98 13.83 79 17475 60889 64420289
Cholestasis 59.35 13.83 67 17487 44805 64436373
Cardiac failure 57.03 13.83 117 17437 132256 64348922
Blood glucose increased 55.00 13.83 97 17457 97976 64383202
Renal failure 52.28 13.83 137 17417 181551 64299627
Pancreatitis acute 50.00 13.83 60 17494 42795 64438383
Bradyphrenia 48.90 13.83 31 17523 9375 64471803
Oesophageal perforation 48.83 13.83 16 17538 1025 64480153
Drug ineffective 44.79 13.83 102 17452 840145 63641033
Coronavirus infection 43.98 13.83 24 17530 5506 64475672
Eosinophilia 43.91 13.83 53 17501 38023 64443155
Prothrombin consumption time prolonged 43.69 13.83 8 17546 38 64481140
Anaemia 42.86 13.83 210 17344 378470 64102708
Transcription medication error 41.31 13.83 11 17543 340 64480838
Product prescribing error 40.52 13.83 49 17505 35220 64445958
Hypoglycaemic encephalopathy 39.50 13.83 12 17542 600 64480578
Confusional state 38.71 13.83 157 17397 260987 64220191
Rash maculo-papular 38.04 13.83 55 17499 46971 64434207
Polymerase chain reaction 35.34 13.83 8 17546 123 64481055
Vascular purpura 34.87 13.83 16 17538 2540 64478638
Pain 34.73 13.83 61 17493 553450 63927728
Medication error 34.11 13.83 54 17500 49912 64431266
Acute coronary syndrome 32.91 13.83 33 17521 19277 64461901
Erythromelalgia 32.43 13.83 8 17546 181 64480997
Arthralgia 32.25 13.83 44 17510 442216 64038962
Completed suicide 31.29 13.83 11 17543 224403 64256775
Hyperkinetic heart syndrome 30.16 13.83 7 17547 121 64481057
Fatigue 30.11 13.83 104 17450 748626 63732552
Headache 30.00 13.83 62 17492 529405 63951773
Dysarthria 28.55 13.83 55 17499 59351 64421827
Joint swelling 27.65 13.83 12 17542 215370 64265808
Pericardial haemorrhage 27.60 13.83 16 17538 4120 64477058
Toxic skin eruption 27.56 13.83 30 17524 19254 64461924
Rheumatoid arthritis 26.71 13.83 6 17548 164288 64316890
Peripheral swelling 26.30 13.83 12 17542 209141 64272037
Pancreatic carcinoma 26.00 13.83 22 17532 10351 64470827
Dehydration 25.75 13.83 122 17432 216641 64264537
Drug hypersensitivity 25.06 13.83 17 17537 237798 64243380
Infusion related reaction 24.81 13.83 7 17547 164460 64316718
Blood glucose decreased 24.74 13.83 31 17523 23092 64458086
Sinusitis 24.39 13.83 5 17549 145923 64335255
Agranulocytosis 24.30 13.83 40 17514 38189 64442989
Hypokinesia 24.04 13.83 26 17528 16570 64464608
Dermatitis bullous 23.16 13.83 22 17532 12032 64469146
Off label use 22.73 13.83 92 17462 632714 63848464
Drug reaction with eosinophilia and systemic symptoms 22.24 13.83 47 17507 54170 64427008
Lung disorder 21.92 13.83 50 17504 60650 64420528
Hyperthermia 21.89 13.83 24 17530 15526 64465652
Haemoglobinuria 21.73 13.83 8 17546 725 64480453
Renal impairment 21.44 13.83 83 17471 134934 64346244
Pancreatitis 21.42 13.83 49 17505 59558 64421620
Diabetic ketoacidosis 21.40 13.83 33 17521 29812 64451366
Thrombocytopenia 21.04 13.83 118 17436 223683 64257495
Nasopharyngitis 20.68 13.83 14 17540 196059 64285119
Shock haemorrhagic 20.39 13.83 24 17530 16767 64464411
Ischaemic cardiomyopathy 20.29 13.83 16 17538 6822 64474356
Supraventricular extrasystoles 20.09 13.83 15 17539 5900 64475278
Death 20.06 13.83 66 17488 482639 63998539
Arteriovenous fistula site haematoma 19.84 13.83 4 17550 34 64481144
Interstitial lung disease 19.72 13.83 65 17489 97667 64383511
Poverty of speech 19.72 13.83 7 17547 572 64480606
Glycosuria 19.31 13.83 10 17544 2064 64479114
Hepatitis fulminant 19.31 13.83 15 17539 6259 64474919
Product dose omission issue 19.11 13.83 15 17539 194732 64286446
Haematoma 18.86 13.83 40 17514 46210 64434968
Arthropathy 18.52 13.83 5 17549 120962 64360216
Renal tubular necrosis 18.08 13.83 26 17528 22084 64459094
Disorientation 18.00 13.83 44 17510 55784 64425394
Chronic kidney disease 17.99 13.83 45 17509 57874 64423304
Loss of consciousness 17.96 13.83 84 17470 148281 64332897
Dermatitis exfoliative generalised 17.89 13.83 14 17540 5902 64475276
Prurigo 17.81 13.83 8 17546 1209 64479969
Bradycardia 17.41 13.83 71 17483 118148 64363030
Euglycaemic diabetic ketoacidosis 16.79 13.83 13 17541 5397 64475781
Resting tremor 16.66 13.83 8 17546 1406 64479772
Maternal exposure during pregnancy 16.62 13.83 3 17551 95881 64385297
Drug intolerance 16.60 13.83 16 17538 187976 64293202
Atrioventricular block complete 16.50 13.83 20 17534 14398 64466780
Subacute cutaneous lupus erythematosus 15.80 13.83 10 17544 3015 64478163
Hypoglycaemic unconsciousness 15.24 13.83 7 17547 1114 64480064
Somnambulism 15.19 13.83 12 17542 5129 64476049
Acute pulmonary oedema 15.04 13.83 18 17536 12791 64468387
Melaena 14.98 13.83 40 17514 53508 64427670
Hypomagnesaemia 14.86 13.83 32 17522 37344 64443834
Haematuria 14.78 13.83 43 17511 60428 64420750
Blood lactic acid increased 14.55 13.83 16 17538 10385 64470793
Therapeutic product effect incomplete 14.54 13.83 5 17549 103477 64377701
White blood cell count decreased 14.44 13.83 13 17541 157824 64323354
Extrasystoles 14.43 13.83 13 17541 6645 64474533
Cardio-respiratory arrest 14.41 13.83 59 17495 98334 64382844
Muscle haemorrhage 14.01 13.83 12 17542 5741 64475437
Therapeutic product effect decreased 13.91 13.83 7 17547 115344 64365834

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A10BD14 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BX02 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Other blood glucose lowering drugs, excl. insulins
FDA EPC N0000175428 Glinide
FDA MoA N0000175448 Potassium Channel Antagonists
MeSH PA D007004 Hypoglycemic Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Diabetes mellitus type 2 indication 44054006 DOID:9352
Alcoholism contraindication 7200002
Asthenia contraindication 13791008
Myocardial infarction contraindication 22298006 DOID:5844
Acute vomiting contraindication 23971007
Severe adrenal insufficiency contraindication 24867002
Alcohol intoxication contraindication 25702006
Shock contraindication 27942005
Dehydration contraindication 34095006
Infectious disease contraindication 40733004
Ketoacidosis contraindication 56051008
Acute nephropathy contraindication 58574008
Metabolic acidosis contraindication 59455009
Acute infectious disease contraindication 63171007
Hypopituitarism contraindication 74728003 DOID:9406
Cardiogenic shock contraindication 89138009
Kidney disease contraindication 90708001 DOID:557
Lactic acidosis contraindication 91273001 DOID:3650
Cobalamin deficiency contraindication 190634004
Decompensated cardiac failure contraindication 195111005
Disease of liver contraindication 235856003 DOID:409
Hypoglycemic disorder contraindication 237630007
Sepsis syndrome contraindication 238150007
Primary adrenocortical insufficiency contraindication 373662000
Adrenal cortical hypofunction contraindication 386584007 DOID:10493
Fever contraindication 386661006
Surgical procedure contraindication 387713003
Severe diarrhea contraindication 409587002
Breastfeeding (mother) contraindication 413712001
Traumatic injury contraindication 417746004
Radiography with IV Iodinated Contrast Agent contraindication
Severe Hypoxemia contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.43 acidic
pKa2 3.8 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Sulfonylurea receptor 1, Kir6.2 Ion channel BLOCKER Ki 9.14 WOMBAT-PK CHEMBL
ATP-binding cassette sub-family C member 8 Ion channel Kd 7.30 CHEMBL
Solute carrier organic anion transporter family member 1B1 Transporter WOMBAT-PK
Solute carrier family 22 member 1 Transporter IC50 5.04 CHEMBL
Sulfonylurea receptor 2, Kir6.2 Ion channel BLOCKER Ki 8.81 WOMBAT-PK

External reference:

IDSource
4021119 VUID
N0000148573 NUI
D00594 KEGG_DRUG
4021119 VANDF
C0246689 UMLSCUI
CHEBI:8805 CHEBI
BJX PDB_CHEM_ID
CHEMBL1272 ChEMBL_ID
DB00912 DRUGBANK_ID
C072379 MESH_SUPPLEMENTAL_RECORD_UI
6841 IUPHAR_LIGAND_ID
6818 INN_ID
668Z8C33LU UNII
65981 PUBCHEM_CID
219335 RXNORM
11576 MMSL
120643 MMSL
5416 MMSL
d04267 MMSL
007421 NDDF
109074004 SNOMEDCT_US
386964000 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Repaglinide HUMAN PRESCRIPTION DRUG LABEL 1 0574-0240 TABLET 0.50 mg ORAL ANDA 25 sections
Repaglinide HUMAN PRESCRIPTION DRUG LABEL 1 0574-0241 TABLET 1 mg ORAL ANDA 25 sections
Repaglinide HUMAN PRESCRIPTION DRUG LABEL 1 0574-0242 TABLET 2 mg ORAL ANDA 25 sections
REPAGLINIDE HUMAN PRESCRIPTION DRUG LABEL 1 51991-853 TABLET 0.50 mg ORAL ANDA 24 sections
REPAGLINIDE HUMAN PRESCRIPTION DRUG LABEL 1 51991-854 TABLET 1 mg ORAL ANDA 24 sections
REPAGLINIDE HUMAN PRESCRIPTION DRUG LABEL 1 51991-855 TABLET 2 mg ORAL ANDA 24 sections
Prandin HUMAN PRESCRIPTION DRUG LABEL 1 54868-5381 TABLET 2 mg ORAL NDA 21 sections
Prandin HUMAN PRESCRIPTION DRUG LABEL 1 54868-6439 TABLET 1 mg ORAL NDA 21 sections
Repaglinide Human Prescription Drug Label 1 57237-157 TABLET 0.50 mg ORAL ANDA 25 sections
Repaglinide Human Prescription Drug Label 1 57237-158 TABLET 1 mg ORAL ANDA 25 sections
Repaglinide Human Prescription Drug Label 1 57237-159 TABLET 2 mg ORAL ANDA 25 sections
Repaglinide HUMAN PRESCRIPTION DRUG LABEL 1 57664-745 TABLET 1 mg ORAL ANDA 25 sections
Repaglinide HUMAN PRESCRIPTION DRUG LABEL 1 57664-747 TABLET 2 mg ORAL ANDA 25 sections
REPAGLINIDE HUMAN PRESCRIPTION DRUG LABEL 1 60429-484 TABLET 0.50 mg ORAL ANDA 24 sections
REPAGLINIDE HUMAN PRESCRIPTION DRUG LABEL 1 60429-485 TABLET 1 mg ORAL ANDA 24 sections
REPAGLINIDE HUMAN PRESCRIPTION DRUG LABEL 1 60429-486 TABLET 2 mg ORAL ANDA 24 sections
Repaglinide HUMAN PRESCRIPTION DRUG LABEL 1 60687-560 TABLET 1 mg ORAL ANDA 25 sections
Prandin HUMAN PRESCRIPTION DRUG LABEL 1 60846-882 TABLET 1 mg ORAL ANDA 28 sections
Prandin HUMAN PRESCRIPTION DRUG LABEL 1 60846-884 TABLET 2 mg ORAL ANDA 28 sections
Repaglinide HUMAN PRESCRIPTION DRUG LABEL 1 63629-8363 TABLET 2 mg ORAL ANDA 25 sections
Repaglinide HUMAN PRESCRIPTION DRUG LABEL 1 63629-8363 TABLET 2 mg ORAL ANDA 25 sections
Repaglinide HUMAN PRESCRIPTION DRUG LABEL 1 63629-8447 TABLET 0.50 mg ORAL ANDA 25 sections
Repaglinide HUMAN PRESCRIPTION DRUG LABEL 1 63629-8447 TABLET 0.50 mg ORAL ANDA 25 sections
Repaglinide HUMAN PRESCRIPTION DRUG LABEL 1 63629-8448 TABLET 1 mg ORAL ANDA 25 sections
Repaglinide HUMAN PRESCRIPTION DRUG LABEL 1 63629-8448 TABLET 1 mg ORAL ANDA 25 sections
Repaglinide HUMAN PRESCRIPTION DRUG LABEL 1 63629-8449 TABLET 2 mg ORAL ANDA 25 sections
Repaglinide HUMAN PRESCRIPTION DRUG LABEL 1 63629-8449 TABLET 2 mg ORAL ANDA 25 sections
Repaglinide Human Prescription Drug Label 1 65862-670 TABLET 0.50 mg ORAL ANDA 27 sections
Repaglinide Human Prescription Drug Label 1 65862-670 TABLET 0.50 mg ORAL ANDA 27 sections
Repaglinide Human Prescription Drug Label 1 65862-671 TABLET 1 mg ORAL ANDA 27 sections